The bile acid lithocolic acid acts as an agonist on the GPBA GPCR, also known as GPR131 or TGR5, to increase intracellular cAMP in cells that express the receptor. Bile acids and other GPBA ligands increase glucagon-like peptide-1 (GLP-1) secretion from intestinal cells. Although Type II diabetics have impaired ability to secrete GLP-1, their responsiveness to this compound, which enhances the effects of insulin, is normal. Thus GPBA agonists are of interest in developing therapeutics for diabetes. Interestingly, it has been suggested that the anti-diabetic effect of olive leaves could in part be mediated by agonist activity at GPBA receptors by oleanolic acid.